Fenwick Represents Cepheid in $345M Convertible Senior Notes

February 10, 2014

Experience Profile

​Fenwick & West represented Cepheid (Nasdaq: CPHD), a molecular diagnostics company, in its offering of $345 million aggregate principal amount of 1.25% convertible senior notes due in 2021. The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.